City of Hope (T Cell Manufacturing)
Duarte, CA
National Center
215 confirmed programs
· 136 sponsors
· Last scored 2026-11-02
84.0
Signal Score
✓ FDA Inspections (3)
✓ Clinical Trials (215)
○ SEC Filings
○ Press
○ EMA GMP
○ MHRA GMP
Quick Facts: City of Hope (T Cell Manufacturing)
- Signal Score
- 84.0/100 (as of 2026-11-02)
- Quality Compliance
- 97.3/100
- Headquarters
- Duarte, CA
- Modalities
- CAR-T, Cell Therapy
- Active Programs
- 215 confirmed from ClinicalTrials.gov across 136 sponsors
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About City of Hope (T Cell Manufacturing)
CDMO.
Signal Score & Pillar Breakdown
Quality Compliance
97.3
FDA Inspections3 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-08-20)
Operations
98.9
215 active programs across 136 sponsors
Modalities: CAR-T, Cell Therapy
131 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
215 active programs across 136 sponsors · Modalities: CAR-T, Cell Therapy · 131 programs in advanced phases (Phase 2/3)
Programs
215
Sponsors136
ModalitiesCAR-T, Cell Therapy
215 active programs across 136 sponsors
Modalities: CAR-T, Cell Therapy
131 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07285694
AB-3028, a Programmable Circuit T Cell Therapy in Patients...
PHASE1/PHASE2
Active Not Recruiting
View all 215 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability
68.0
Parent company: City of Hope
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: City of Hope
Financial assessment: 68.0/100
Capacity
58.0
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
Sites: Duarte, CA
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Duarte, CA
Modalities: CAR-T, Cell Therapy
Capacity assessment: 58.0/100
City of Hope (T Cell Manufacturing) FDA Inspection History
2025-08
2025-02
2024-12
NAI
VAI
OAI
| Date | Site | Type | 483 citations posted | Classification |
|---|---|---|---|---|
| 2025-08-20 |
Beckman Research Institute, City of Hope
Duarte, California
Company-level
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2025-02-07 |
City Of Hope National Medical Center
Duarte, California
Facility-linked
|
Human Cellular, Tissue, and Gene Therapies | Not posted | No Action Indicated (NAI) |
| 2024-12-09 |
City of Hope National Medical Center
Irvine, California
Facility-linked
|
Blood and Blood Products | Not posted | No Action Indicated (NAI) |
Source: FDA Data Dashboard · Retrieved Nov 21, 2026
City of Hope (T Cell Manufacturing) FDA 483 Findings 3 observations · 2025-08-20 → 2025-08-20 ?
By subsystem
By severity
- 3 — Moderate: 2
- 2 — Minor: 1
- Repeat observations: 0
Most severe findings
-
Suitability of testing methods verified
"The suitability of all testing methods is not verified under actual conditions of use."
-
Scientifically sound laboratory controls
"Laboratory controls do not include the establishment of scientifically sound and appropriate standards designed to assure that components conform to appropriate standards of identity, strength, quality and purity."
-
Procedures not in writing, fully followed
"The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed."
Clinical Activity 215 studies
NCT07711327
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine...
NA
Not Yet Recruiting
NCT07702578
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing...
PHASE3
Recruiting
NCT07227155
The HOPE Biobank Resource (BMT CTN 2402 HOPE)
NA
Recruiting
NCT02943642
Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in...
PHASE2
Withdrawn
NCT07544589
A Phase 1 Study Evaluating DISP-10 in Participants With Advanced...
PHASE1
Recruiting
NCT07387367
A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus...
PHASE3
Recruiting
NCT07227415
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404...
PHASE1/PHASE2
Recruiting
NCT07219212
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in...
PHASE1
Recruiting
NCT07285694
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration...
PHASE1/PHASE2
Active Not Recruiting
NCT04119024
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of...
PHASE1
Recruiting
NCT04119024
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of...
PHASE1
Recruiting
NCT06976736
A Long Term Follow-up Study of TScan TCR-T Products
NA
Recruiting
NCT06859424
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based...
PHASE2
Recruiting
NCT07075185
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and...
PHASE1
Recruiting
NCT07038447
A Study of KITE-363 in Participants With Refractory Autoimmune Diseases
PHASE1
Enrolling By Invitation
NCT06552416
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
PHASE1
Recruiting
NCT06533579
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
PHASE1/PHASE2
Recruiting
NCT06657144
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other...
PHASE1
Recruiting
NCT06805305
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult...
PHASE2
Recruiting
NCT06528301
A Phase 1 Study of UB-VV111 With and Without Rapamycin in...
PHASE1
Recruiting
+ 195 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data. This company's careers site asks automated readers not to collect it (robots.txt), and we respect that.
Source:
public careers pages
· Checked Nov 20, 2026
Frequently Asked Questions About City of Hope (T Cell Manufacturing)
How many FDA inspections does City of Hope (T Cell Manufacturing) have on record?
CDMO Signal tracks 3 FDA inspections for City of Hope (T Cell Manufacturing), sourced from the FDA inspection database. See the full inspection history above.
Has City of Hope (T Cell Manufacturing) received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for City of Hope (T Cell Manufacturing).
How many clinical programs is City of Hope (T Cell Manufacturing) linked to?
City of Hope (T Cell Manufacturing) is associated with 215 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is City of Hope (T Cell Manufacturing)'s CDMO Signal Score?
City of Hope (T Cell Manufacturing) has a Signal Score of 84/100, based on quality, operations, financial stability, and capacity data.
Evaluating City of Hope (T Cell Manufacturing) for a manufacturing program?
Use the free AI matchmaker to compare City of Hope (T Cell Manufacturing) against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Similar CDMOs
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
Cellares
South San Francisco, CA
Signal Score: 59.0
CAR-T, Cell Therapy
Poseida Therapeutics (CDMO)
San Diego, CA
Signal Score: 58.7
CAR-T, Cell Therapy, Gene Editing
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Minaris Advanced Therapies
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
Signal Score: 83.1
CAR-T, Cell Therapy
Compare City of Hope (T Cell Manufacturing) with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.